SCHEMBL19625922

SCHEMBL19625922

COC(=O)[C@H]1CC[C@H](CCl)CC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.43
ALDH1A1 P00352 2/20 0.41
GAA P10253 1/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
CHRNB2 P17787 2/20 0.38
CHRNA4 P43681 2/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA7 P36544 1/20 0.38
POLB P06746 1/20 0.38
HPGD P15428 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PPM1B O75688 1/20 0.36
PTPN1 P18031 1/20 0.36
PPP1CC P36873 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28953068 1.00 TP53 (0.43) TP53ALDH1A1GAASMN1; SMN2CHRNB2
Ammonia Solution, Strong SCHEMBL2359960 0.98 TP53 (0.42) TP53ALDH1A1GAASMN1; SMN2CHRNB2
SCHEMBL5543322 0.83 GAA (0.47) TP53ALDH1A1GAASMN1; SMN2CHRNB2
SCHEMBL15200264 0.83 GAA (0.47) TP53ALDH1A1GAASMN1; SMN2CHRNB2
SCHEMBL17118123 0.83 TP53 (0.46) TP53ALDH1A1GAASMN1; SMN2CHRNB2
SCHEMBL358775 0.83 GAA (0.47) TP53ALDH1A1GAASMN1; SMN2CHRNB2
SCHEMBL14305169 0.83 TP53 (0.46) TP53ALDH1A1GAASMN1; SMN2CHRNB2
SCHEMBL2948892 0.82 TP53 (0.56) TP53ALDH1A1GAASMN1; SMN2CHRNB2
SCHEMBL244740 0.82
SCHEMBL2200767 0.82 TP53 (0.56) TP53ALDH1A1GAASMN1; SMN2CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200039921-A1 ANTIFIBRINOLYTIC COMPOUNDS CHIBBER BAKSHY A (US) 2020-02-06 US disclosed
US-10202331-B2 Antifibrinolytic compounds THROMBOLYTICS LLC (US) 2019-02-12 US disclosed
US-20170334834-A1 ANTIFIBRINOLYTIC COMPOUNDS THROMBOLYTICS, LLC (US) 2017-11-23 US disclosed
US-20170334834-A1 ANTIFIBRINOLYTIC COMPOUNDS THROMBOLYTICS, LLC (US) 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10202331-B2 Antifibrinolytic compounds F2, FGB, SERPINC1 TP53 2911/4885ALDH1A1 3804/4885GAA 2471/4885
US-20170334834-A1 ANTIFIBRINOLYTIC COMPOUNDS F2, SERPINC1, F12 TP53 4854/4885ALDH1A1 930/4885GAA 1446/4885
US-20200039921-A1 ANTIFIBRINOLYTIC COMPOUNDS F2, SERPINC1, F12 TP53 4854/4885ALDH1A1 930/4885GAA 1446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.